search
Back to results

Prophylactic Minimally Invasive Surfactant Evaluation (PreProMISe)

Primary Purpose

Respiratory Distress Syndrome, Newborn, Premature Birth

Status
Not yet recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Poractant Alfa
Sponsored by
NorthShore University HealthSystem
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Distress Syndrome, Newborn focused on measuring Respiratory Distress Syndrome, surfactant, Minimally invasive Surfactant Therapy

Eligibility Criteria

undefined - 15 Minutes (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Gestational age <30 weeks Antenatal consent from Parent Exclusion Criteria: Congenital anomalies Alternate cause of respiratory distress

Sites / Locations

  • Northshore University Healthsystem

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Prophylactic Surfactant via Minimally Invasive Technique

Rescue Surfactant via Minimally Invasive Technique

Arm Description

Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).

The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.

Outcomes

Primary Outcome Measures

Endotracheal Intubation
Oxygen requirement > 45% requiring endotracheal intubation

Secondary Outcome Measures

Bronchopulmonary dysplasia
Oxygen requirement to 36 weeks corrected age

Full Information

First Posted
July 27, 2023
Last Updated
September 27, 2023
Sponsor
NorthShore University HealthSystem
Collaborators
Chiesi USA, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT06007547
Brief Title
Prophylactic Minimally Invasive Surfactant Evaluation
Acronym
PreProMISe
Official Title
Prophylactic Minimally Invasive Surfactant Evaluation
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
October 31, 2025 (Anticipated)
Study Completion Date
July 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
NorthShore University HealthSystem
Collaborators
Chiesi USA, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
Detailed Description
RESEARCH DESIGN Multicenter, randomized, controlled trial. Northshore Evanston Hospital will be the primary site. It is hoped that Northwest Community, University of Chicago, Edwards Hospital, Advocate Park Ridge, Advocate Oak Lawn and Advocate Illinois Masonic will also join the study. RECRUITMENT Entry criteria Inborn preterm infants 22 0/7-29 6/7 weeks' gestation, with be randomized to prophylactic Minimally Invasive Surfactant Therapy (MIST) in the delivery room compared to rescue MIST if fraction of inspired oxygen (FiO2) ≥0.30 at less than 48 hours of age. Babies in both groups will be managed on nasal continuous positive airway pressure (NCPAP) pressures of 5-8 cm water. Exclusion criteria Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress. Babies who require emergent intubation in the delivery room will not be enrolled in the interventions. Parental Consent will be obtained prior to birth. Once delivery is imminent infant will be randomized to immediate versus rescue surfactant administration via MIST. Randomization will be in blocks of 6 and using cards with created by a web based randomizer. Infants who require emergent intubation in the delivery room will not be enrolled in the interventions but their clinical outcomes will be assessed the same as the babies who receive the intervention. There will be three gestational age strata (22-23 weeks, 24-26 weeks and 27-29 weeks). Twins and higher order multiples will be randomized independently. Babies in the lowest gestational age strata will not be enrolled at a center until 5 babies at that center have been enrolled in either of the other groups. INTERVENTION Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16 Gauge Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes). The infants will be stabilized and placed on NCPAP or High flow Nasal Cannula (HFNC). Briefly the MIST procedure is as follows: the angiocath is inserted to an appropriate depth under direct laryngoscopy, the laryngoscope is removed, a carbon dioxide (CO2) detector is placed on the end of the catheter with a endotracheal tube adaptor. If the color changes then adaptor and detector are removed and the surfactant is instilled over about 1 minute and the catheter is removed. The infant is maintained on NCPAP/HFNC during the procedure. Infants of both groups will be supported via HFNC or NCPAP in the delivery room and then transitioned to NCPAP in the neonatal intensive care unit (NICU). The control group will be given surfactant via MIST if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life. A second dose of poractant alfa (Curosurf), at a dosage of 100mg/kg, will be administered via MIST to both groups if their fiO2 reaches the threshold of 30% between 6 and 48 hours after the first dose. No further surfactant should be given in the first 7 days unless the infant reaches the intubation criteria. POST-INTERVENTION MANAGEMENT Other than the requirement to adhere to intubation criteria in the first week, and in some cases perform a room air trial at 36 weeks corrected gestation, management will be at the discretion of the clinical team. Titration of CPAP pressure is encouraged, with a permitted maximum of 8 cm H2O. Use of nasal intermittent positive-pressure ventilation (NIPPV) is allowable for apnea, but discouraged for Respiratory Distress Syndrome (RDS) and should only be after at least one dose of surfactant has been given. Early caffeine therapy is expected. Criteria for intubation: Enrolled infants on CPAP will be intubated if: FiO2 ≥0.45 for 15 minutes, or if there is unremitting apnea (> 6 episodes/hour requiring intervention or in the opinion of the treating physician) or persistent respiratory acidosis (pH<7.25 and partial pressure of carbon dioxide (pCO2) >60) on blood gasses at least 30 minutes apart or metabolic acidosis refractory to treatment. Need for an anesthetic or an intervention requiring intubation These criteria apply during the first week of life, and to the first episode of intubation only. If the infant is intubated it is expected that another dose of surfactant will be administered. OUTCOMES Primary outcome: Intubation in the first 7 days of age. Secondary outcomes: Respiratory Incidence of composite outcome of death or physiological bronchopulmonary dysplasia (BPD). Durations of mechanical respiratory support, CPAP, high flow nasal cannula, (HFNC), oxygen therapy. Pneumothorax or pulmonary hemorrhage. Non respiratory neonatal morbidities intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, and patent ductus arteriosus. Corrected age at discharge, length of hospital stay (a proxy for cost). Neonatal follow up data. The above data will be collected until discharge. Babies born between 22 and 29 weeks are routinely followed by our developmental follow up clinic. The information from the 2-year developmental clinic visit will be recorded by the study. SAMPLE SIZE 200, 50 being from NorthShore. Between 2018 and 2022 65% of the babies in this gestational age had an endotracheal tube inserted at Evanston Hospital, and were ventilated. Detection of a reduction of 25% (from 65% to 40%) with a 90% power and α = 0.05 (two-sided) would require 82 subjects per arm. It is anticipated that patient recruitment should take 2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Distress Syndrome, Newborn, Premature Birth
Keywords
Respiratory Distress Syndrome, surfactant, Minimally invasive Surfactant Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Comparison of prophylaxis compared to rescue surfactant, administered using a minimally invasive technique, in premature infants less that 30 weeks gestation
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Prophylactic Surfactant via Minimally Invasive Technique
Arm Type
Experimental
Arm Description
Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).
Arm Title
Rescue Surfactant via Minimally Invasive Technique
Arm Type
Active Comparator
Arm Description
The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.
Intervention Type
Drug
Intervention Name(s)
Poractant Alfa
Other Intervention Name(s)
Minimally Invasive Surfactant Therapy
Intervention Description
Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
Primary Outcome Measure Information:
Title
Endotracheal Intubation
Description
Oxygen requirement > 45% requiring endotracheal intubation
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Bronchopulmonary dysplasia
Description
Oxygen requirement to 36 weeks corrected age
Time Frame
36 weeks corrected gestational age

10. Eligibility

Sex
All
Maximum Age & Unit of Time
15 Minutes
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Gestational age <30 weeks Antenatal consent from Parent Exclusion Criteria: Congenital anomalies Alternate cause of respiratory distress
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew Derrick, MBBS
Phone
8475702920
Email
mderrick@northshore.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Derrick, MBBS
Organizational Affiliation
Northshore Univ Healthsystem
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northshore University Healthsystem
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Derrick, mbbs
Phone
847-570-2920
Email
mderrick@northshore.org

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34902013
Citation
Dargaville PA, Kamlin COF, Orsini F, Wang X, De Paoli AG, Kanmaz Kutman HG, Cetinkaya M, Kornhauser-Cerar L, Derrick M, Ozkan H, Hulzebos CV, Schmolzer GM, Aiyappan A, Lemyre B, Kuo S, Rajadurai VS, O'Shea J, Biniwale M, Ramanathan R, Kushnir A, Bader D, Thomas MR, Chakraborty M, Buksh MJ, Bhatia R, Sullivan CL, Shinwell ES, Dyson A, Barker DP, Kugelman A, Donovan TJ, Tauscher MK, Murthy V, Ali SKM, Yossuck P, Clark HW, Soll RF, Carlin JB, Davis PG; OPTIMIST-A Trial Investigators. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021 Dec 28;326(24):2478-2487. doi: 10.1001/jama.2021.21892.
Results Reference
background
PubMed Identifier
2000109
Citation
Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, Sinkin RA, Bartoletti A, Dweck HS, Horgan MJ, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med. 1991 Mar 28;324(13):865-71. doi: 10.1056/NEJM199103283241301.
Results Reference
background
PubMed Identifier
20084586
Citation
Kribs A, Hartel C, Kattner E, Vochem M, Kuster H, Moller J, Muller D, Segerer H, Wieg C, Gebauer C, Nikischin W, Wense Av, Herting E, Roth B, Gopel W. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr. 2010 Jan-Feb;222(1):13-7. doi: 10.1055/s-0029-1241867. Epub 2010 Jan 18.
Results Reference
background
PubMed Identifier
8516091
Citation
Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, Jung AL, King K, Mueller D. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics. 1993 Jul;92(1):90-8.
Results Reference
background
PubMed Identifier
20472939
Citation
SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network; Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID 3rd, Buchter S, Sanchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1970-9. doi: 10.1056/NEJMoa0911783. Epub 2010 May 16. Erratum In: N Engl J Med. 2010 Jun 10;362(23):2235.
Results Reference
background

Learn more about this trial

Prophylactic Minimally Invasive Surfactant Evaluation

We'll reach out to this number within 24 hrs